药物重定位和重定位用于帕金森病的疾病修饰效应
Seong Ho Jeong1, Phil Hyu Lee2,3
1Department of Neurology, Inje University Sanggye Paik Hospital, Seoul, Korea.
Journal of movement disorders
|February 6, 2025
概括
重用现有药物为开发帕金森病 (PD) 疾病修饰疗法提供了一个有希望的途径. 虽然一些候选人显示出潜力,试验设计和理解PD复杂性的挑战仍然存在.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 帕金森病 (PD) 是一种流行的神经退行性疾病,其特征是神经元损失和α-synuclein聚合.
- 目前的PD治疗主要是治疗症状,缺乏疾病修饰能力.
- 开发新疗法受到PD异质性,缺乏生物标志物和复杂的病理生理学的阻碍.
研究的目的:
- 审查重定向药物的潜力,作为帕金森病的疾病修饰疗法.
- 评估优先考虑的候选药物的机制,临床前证据和临床试验结果.
- 突出在开发新型PD治疗中持续存在的挑战和机会.
主要方法:
- 对PD重用药物的临床前和临床研究的文献综述.
- 在不同试验阶段分析药物机制,安全性概况和疗效.
- 评估PD药物开发和试验设计中的挑战.
主要成果:
- 药物重定向策略利用已知安全性配置文件的现有药物来加速PD治疗的发展.
- 几种药物类别,包括GLP-1受体激动剂和DPP-4抑制剂,显示出临床前的前景.
- 尽管早期结果令人鼓舞,但许多晚期临床试验都遭遇挫折,这凸显了PD的复杂性.
结论:
- 重用药物代表了推进帕金森病治疗的可行策略.
- 进一步的研究和创新的临床试验设计对于成功至关重要.
- 解决PD的多面性质是开发有效的疾病修饰疗法的关键.
相关概念视频
Parkinson's Disease: Treatment
192
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
192
Parkinson's Disease: Overview
447
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
447
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Alzheimer's Disease: Treatment
158
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
158
Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drug Therapy
37
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
37


